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ABSTRACT
Aims/Introduction: Natural killer (NK) cells are cytotoxic lymphocytes critical to human
immunity. Previous studies showed correlations between NK cell function and blood glu-
cose concentrations. The purpose of the present study was to assess the NK cell activity
and various metabolic parameters in people with type 2 diabetes, prediabetes and normal
glucose tolerance.
Materials and Methods: A total of 49 participants were enrolled in the study. Anthro-
pometric and biochemical parameters including age, sex, body mass index, smoking sta-
tus, blood pressure, fasting plasma glucose, C-peptide, insulin, glycated hemoglobin, total
cholesterol, triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein
cholesterol were assessed. The 75 g oral glucose tolerance test was carried out for 2-h
postload glucose level. Homeostatic model assessment was calculated for insulin resis-
tance and b-cell function. NK cell activity was measured by detecting the circulating inter-
feron-gamma level secreted from NK cells.
Results: NK cell activity was lower in patients with type 2 diabetes (768.01 – 650.35)
compared with those with prediabetes (2,396.08 – 653.76, P < 0.001) and normal glucose
tolerance (2,435.31 – 633.22, P < 0.001). In patients with type 2 diabetes, there was a sig-
nificant inverse linear relationship between NK cell activity and fasting plasma glucose, gly-
cated hemoglobin, and 2-h postload glucose level (all P < 0.001). Multiple regression
analysis showed glycated hemoglobin to be an independent predictor of NK cell activity
in patients with type 2 diabetes.
Conclusions: Compared with individuals with normal glucose tolerance or prediabetes,
type 2 diabetes patients have a reduced NK cell activity, and it is significantly related to
glucose control.
INTRODUCTION
People with type 2 diabetes mellitus have increased morbidity
and mortality from diabetic vascular complications1. Recent
studies have shown that patients with diabetes are also prone
to various cancers, and efforts are being made to understand
the underlying mechanisms for this increased cancer inci-
dence2–4. The chronic inflammatory state in diabetes patients
might be involved in the impaired immune function and, con-
sequently, the higher susceptibility to infection5,6. Natural killer
(NK) cell activity, in particular, has been shown to be involved
in the immune dysfunction and increased risk of cancer in
diabetes patients7.
NK cells engage in innate immunity to remove pathogens
and cancer cells8. They also release cytokines to transmit adap-
tive immunity9. Previous research has shown that different
levels of cytokines produced by NK cells result in various levels
of cell toxicity. NK cells, which strongly express cytokines, have
strong cytotoxicity to target cells, whereas cells that have
degraded cytokine expression have little or none of this func-
tion10. A method was recently developed to easily assess the
activity of NK cells by measuring the level of secreted inter-
feron-gamma (IFN-c) derived from NK cells7. NK cell activity,Received 23 August 2018; revised 28 November 2018; accepted 3 January 2019
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expressed as a concentration of serum IFN-c, is directly related
to changes in the function and level of NK cells, and can indi-
cate the degree of innate and adaptive immunity11. In light of
this, several recent studies showed that the decline in NK cell
activity is related to various types of cancer. As a result, NK
cells are now known to play a role in cancer cell immunologi-
cal surveillance12–14.
Several studies were carried out to evaluate the NK cell func-
tion in diabetes patients. NK cells lost their function when
exposed to hyperglycemia, as in patients with uncontrolled dia-
betes15, and physical inactivity and poor metabolic status were
associated with decreased NK cell activity16. Type 1 diabetes, as
well as type 2 diabetes, patients were presented with a lower
number of NK cells and a decline in NK cell function17–19.
However, little is known about the NK cell activity in patients
with prediabetes – who are in a hyperglycemic state, but not
high enough to be diagnosed with diabetes – nor its relation-
ship with metabolic parameters in these patients.
In the present study, we assessed and compared the NK cell
activity in participants with type 2 diabetes, prediabetes and
normal glucose tolerance (NGT), and analyzed the relationship
between NK cell activity and various metabolic parameters in
these participants.
METHODS
This was a cross-sectional study carried out on individuals
with type 2 diabetes mellitus, prediabetes and NGT who vis-
ited the Endocrine & Diabetes Center of Gangnam Severance
Hospital, Seoul, Korea, from April to June 2017. Type 2 dia-
betes was defined as both previously diagnosed and undiag-
nosed type 2 diabetes mellitus. Diagnosed diabetes mellitus
was based on self-reported responses. The diagnosis of dia-
betes was based on the following American Diabetes Associa-
tion criteria: fasting plasma glucose (FPG) ≥126 mg/dL, or
symptoms of diabetes plus casual plasma glucose ≥200 mg/dL,
or 2-h postload glucose level (2hPG) ≥200 mg/dL during a
75-mg oral glucose tolerance test, or glycated hemoglobin
(HbA1c) ≥6.5%. Prediabetic patients were defined as those
with FPG 100–125 mg/dL, 2hPG 140–199 mg/dL or HbA1c
5.7–6.4%. The NGT group was defined as individuals with
FPG <100 mg/dL, 2hPG <140 mg/dL and HbA1c ≤5.6%.
Individuals with human immunodeficiency virus, splenectomy,
immunosuppressive therapy after organ transplantation, rheu-
matic diseases, Crohn’s disease, use of other drugs that might
affect immune status, severe liver or kidney disease, current
or previous malignancy, blood aminotransferase level of
≥100 IU/L, or blood creatinine level of ≥1.4 mg/dL were
excluded from the study.All procedures carried out in studies
involving human participants were in accordance with the eth-
ical standards of the institutional and/or national research
committee, and with the 1964 Helsinki declaration and its
later amendments or comparable ethical standards. The study
was approved by the institutional review board of Gangnam
Severance Hospital, and was carried out with prior informed
consent from all participants.
The height, weight, and systolic and diastolic blood pressure
were measured in the morning with light clothing without
shoes. Body mass index was calculated as bodyweight in kilo-
grams divided by height in meters squared (kg/m2). Smoking
and past medical and surgical history were assessed at the time
of screening by a single interviewer. Fasting blood samples were
drawn and analyzed for HbA1c, serum glucose, cholesterol,
triglyceride, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, insulin and C-peptide. The 75 g glucose
tolerance test was carried out in all participants for post-loading
glucose, insulin and C-peptide. To indirectly evaluate the insu-
lin secretion function of pancreas b-cells and insulin resistance
in the human body, the following formula was calculated using
homeostatic model assessment (HOMA)20.
HOMA-IR ¼ Fasting blood insulin ðuU/mLÞ
 fasting plasma glucose ðmmol/mLÞ=22:5
HOMA-%B ¼ ð20 fasting blood insulin ðuU/mLÞÞ=
ðfasting plasma glucose ðmmol/mLÞ  3:5Þ
NK cell activity was measured using the NK-Vue Kit
(ATgen, Sungnam, Korea)7. A total of 1 mL of whole blood
was collected from all participants and placed in an NK-Vue
Tube, which is a vacuum filter containing Promoca. To
ensure sufficient blood coating on the entire inner surface of
the tube, it was gently mixed 10 times and then placed in an
incubator at 37°C within 30 min. To ensure successful secre-
tion of IFN-c from activated NK cells, NK-Vue Tubes were
set up for 24 h in an incubator. The supernatant was then col-
lected with a pipette and transferred to a 1.5 mL tube. After
centrifugation at 16,000 r.c.f. for >1 min, the supernatant was
collected in another 1.5 mL tube, and sent to enzyme-linked
immunospecific assay plates to measure and quantify IFN-c
levels released from NK cells7,21.
Statistical analysis
Statistical analysis was carried out with the SPSS software (ver-
sion 23.0; SPSS Inc., Chicago, IL, USA). The baseline character-
istics were expressed as the mean – standard deviation for
continuous variables. The comparison of baseline characteristics
and NK cell activity among patients with type 2 diabetes, predi-
abetes and NGT was carried out by Kruskal–Wallis tests with
Bonferroni’s method and the Mann–Whitney method. Correla-
tion analysis and univariate, multivariate regression analysis
were used to assess relationships between biochemical parame-
ters and NK cell activity, and to identify factors that predict the
NK cell activity. P-values <0.05 were considered statistically
significant.
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RESULTS
Of 49 study participants, 21 had type 2 diabetes, 15 had predia-
betes and 13 had NGT. Patients with diabetes had lower NK
cell activity compared with participants with NGT and predia-
betes (768.01 – 650.35 vs 2435.31 – 633.22, 768.01 – 650.35 vs
2396.08 – 653.76, respectively, all P < 0.001). There was no sig-
nificant difference in NK cell activity between NGT and predia-
betes patients (P = 0.821; Table 1).
Correlation analysis was carried out to determine the associa-
tion between NK cell activity and biochemical parameters.
When all the study participants were included for analysis, NK
cell activity was in negative correlations with FPG (r = -0.745,
P < 0.001), 2hPG (r = -0.778, P < 0.001) and HbA1c (r = -
0.827, P < 0.001). Insulin (r = 0.357, P = 0.023) and HOMA
of b-cell function (HOMA-B; r = 0.787, P < 0.001) showed sig-
nificant positive correlations with NK cell activity. These corre-
lations remained significant after adjusting for age, sex, blood
pressure and smoking status (Table 2).
When diabetes patients were divided into different levels of
glucose control and separate analysis was carried out, NK cell
activity showed significant negative correlations with FPG (r = -
0.705, P = 0.002), 2h-PG (r = -0.795, P = <0.001) and HbA1c
(r = -0.790, P < 0.001), and a significant positive correlation
with HOMA-B (r = 0.649, P = 0.005) after adjusting for age and
sex, blood pressure, and smoking status. In the prediabetes and
NGT groups, no significant relationships were observed between
measured parameters and NK cell activity (Table 2).
Multiple regression analysis with all study participants showed
HbA1c and HOMA-B to be independently associated with
decreased NK cell activity (B = -317.849, 95% confidence inter-
val -384.927 to -250.771, P < 0.001; and B = 5.596, 95% confi-
dence interval 3.199–7.993, P = 0.024, respectively). Among
patients with type 2 diabetes, HbA1c was independently associ-
ated with decreased NK cell activity (B = -280.787, 95% confi-
dence interval -347.053 to -214.521, P < 0.001; Table 3).
DISCUSSION
Impaired immune function has been proposed as a possible
underlying mechanism linking the increased risk of infection
and cancer incidence among diabetes patients3,4. In the present
study, NK cell activity was measured in normal individuals,
prediabetes patients and type 2 diabetes patients, and diabetes
patients had lower NK cell activity compared with the other
two groups, whereas prediabetes and NGT participants had
Table 1 | Baseline characteristics of study participants
Type 2 DM Non-DM P-value
Prediabetes (IGT or IFG) NGT
n 21 15 13
Sex
Men (n) 8 5 4
Women (n) 13 10 9
Age (years) 60.71 – 6.99 58.80 – 10.27 53.69 – 13.76 0.153
Current smoker (%) 38.1 40 15.4 0.307
SBP (mmHg) 128.00 – 14.84 130.53 – 17.79 118.62 – 14.00 0.104
DBP (mmHg) 76.33 – 9.79 84.27 – 14.42 79.00 – 13.47 0.307
BMI (kg/m2) 23.55 – 2.75 24.71 – 2.35 23.10 – 3.54 0.304
FPG (mmol/L) 10.55 – 3.47†‡§ 5.82 – 0.53¶ 5.13 – 0.31 <0.001
HbA1c (%) 8.86 – 1.61†‡§ 5.85 – 0.36¶ 5.35 – 0.35 <0.001
2hPG (mmol/L) 15.54 – 4.75†‡§ 6.94 – 1.48 5.85 – 0.69 <0.001
Total cholesterol (mmol/L) 5.13 – 0.96 4.90 – 0.93 4.86 – 1.15 0.699
Triglyceride (mmol/L) 2.08 – 1.21 1.72 – 0.80 1.43 – 0.79 0.182
HDL cholesterol (mmol/L) 1.31 – 0.33 1.36 – 0.26 1.40 – 0.35 0.708
LDL cholesterol (mmol/L) 3.39 – 0.75 3.25 – 0.92 3.26 – 1.03 0.865
Fasting C-peptide (nmol/L) 0.59 – 0.25†§ 0.75 – 0.23 1.05 – 0.43 0.007
Fasting insulin (pmol/L) 46.53 – 37.78†§ 62.30 – 31.67¶ 118.76 – 129.59 <0.001
HOMA-B 34.40 – 17.09†‡§ 100.33 – 22.56¶ 152.15 – 35.38 <0.001
HOMA-IR 1.89 – 1.45 1.73 – 0.52 2.21 – 0.94 0.224
NK cell activity 768.01 – 650.35†‡§ 2396.08 – 653.76 2435.31 – 633.22 <0.001
Data are presented as the mean (standard deviation). The P-value represents the analysis of variance P for the baseline measures among the
groups. †P < 0.05 between normal glucose tolerance (NGT) and type 2 diabetes mellitus (DM), ‡P < 0.05 between prediabetes (impaired glucose
tolerance [IGT] and impaired fasting glucose [IFG]) and type 2 DM, §P < 0.05 between non-DM (NGT and prediabetes) and type 2 DM, ¶P < 0.05
between NGT and prediabetes (IGT and IFG). 2hPG, 2-h postload glucose; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma
glucose; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HOMA-B, homeostatic model assessment of b-cell function; HOMA-IR,
homeostatic model assessment of insulin resistance; LDL, low-density lipoprotein; NK, natural killer; SBP, systolic blood pressure.
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comparable NK cell activity. Also, NK cell activity was associ-
ated with various parameters related to glucose metabolism
only in diabetes patients.
The present study results are in line with previous studies
that demonstrated a reduced NK cell activity in diabetes
patients compared with controls. The role of NK cells is to
engage in innate immunity and transmit adaptive immunity8,9.
NK cells have characteristic activating receptors, such as
NKp45 and NKG2D, that are activated by contact with ligands
on the surface of infected cells or tumor cells22,23. Several
cytokines, such as interleukin-12 and interleukin-15, promote
NK cell activation through differentiation and maturation24.
Activated NK cells release proteases called perforins and
granzymes25 that have cytotoxic effects on target cells. They
also regulate the immune response by releasing cytokines, such
as IFN-c and tissue necrosis factor-alpha26. Therefore, the
impairment in immune system maintenance, as well as restric-
tion of cancer growth resulting from the reduced NK cell activ-
ity in diabetes patients, might lead to the increased
susceptibility to infectious diseases and cancer.
Meanwhile, there was no difference in NK cell activity
between prediabetes patients and individuals with NGT,
whereas there was a difference between participants with dia-
betes and prediabetes. Also, a significant correlation was noted
only in the diabetes group, and not in the NGT and predia-
betes groups between HbA1c, FPG, 2hPG and NK cell activity.
Table 2 | Correlation analysis between biochemical parameters including natural killer cell activity after adjusting for age, sex, blood pressure and
smoking status
NK cell activity
Type 2 DM Prediabetes NGT All participants
r P-value r P-value r P-value r P-value
BMI 0.193 0.459 0.409 0.240 -0.040 0.925 0.162 0.294
FPG -0.705 <0.001 -0.208 0.565 -0.395 0.333 -0.745 <0.001
HbA1c -0.790 <0.001 -0.470 0.170 -0.751 0.032 -0.827 <0.001
2hPG -0.795 <0.001 0.268 0.453 -0.608 0.109 -0.778 <0.001
Total cholesterol -0.264 0.306 0.032 0.929 -0.407 0.317 -0.245 0.109
Triglyceride -0.003 0.990 0.624 0.054 -0.419 0.302 -0.183 0.235
HDL cholesterol -0.131 0.616 -0.427 0.219 0.332 0.422 0.036 0.818
LDL cholesterol -0.267 0.300 0.188 0.604 -0.448 0.265 -0.186 0.228
Fasting C-peptide -0.350 0.169 0.179 0.621 0.196 0.642 0.219 0.153
Fasting insulin -0.297 0.247 -0.009 0.980 0.749 0.032 0.302 0.046
HOMA-B 0.649 0.005 0.387 0.269 0.244 0.560 0.738 <0.001
HOMA-IR -0.489 0.046 0.187 0.606 0.090 0.833 -0.212 0.166
Data are presented as the mean (standard deviation). 2hPG, 2-h postload glucose; BMI, body mass index; FPG, fasting plasma glucose; HbA1c,
glycated hemoglobin; HDL, high-density lipoprotein; HOMA-B, homeostatic model assessment of b-cell function; HOMA-IR, homeostatic model
assessment of insulin resistance; IR, insulin resistance; LDL, low-density lipoprotein; NK, natural killer; NGT, normal glucose tolerance.
Table 3 | Multiple stepwise regression analysis between natural killer cell activity and biochemical parameters in type 2 diabetes mellitus and all
participants
B (95% CI) b R² P-value
NK cell activity in type 2 DM
FPG 4.499 [0.894, 8.104] 0.432 0.459 0.233
HbA1c -280.787 [-347.053, -214.521] -0.697 0.459 <0.001
2hPG -2.381 [-4.724, -0.038] -0.313 0.459 0.327
HOMA-B 14.096 [4.745, 23.447] 0.370 0.459 0.154
NK cell activity in all participants
FPG 4.702 [0.208, 9.196] 0.277 0.713 0.302
HbA1c -317.849 [-384.927, -250.771] -0.599 0.713 <0.001
2hPG -2.345 [-4.602, -0.088] -0.228 0.713 0.305
Fasting C-peptide -96.849 [-249.246, 55.548] -0.098 0.713 0.529
Fasting insulin 5.527 [-3.117, 14.171] 0.059 0.713 0.526
HOMA-B 5.596 [3.199, 7.993] 0.295 0.713 0.024
Data are presented as the mean. 2hPG, 2-h postload glucose; CI, confidence interval; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin;
HOMA-B, homeostatic model assessment of b-cell function; NK, natural killer.
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In multiple regression analysis, HbA1c independently showed a
significant relationship with NK cell activity only in the diabetes
group. This is in agreement with a previous study that showed
that the cytolytic function of NK cells significantly deteriorates
with the exposure to elevated glucose concentrations in the
range seen in poorly controlled diabetes15. In other words, it
can be inferred that while NK cell activity deteriorates linearly
with the degree of hyperglycemia, hyperglycemia starts to inter-
fere with NK cell activity once it reaches a certain degree, at
least higher than a prediabetes range.
HOMA-B, which indirectly represents the b-cell function
in pancreas, clearly had a significant positive correlation with
NK cell activity in type 2 diabetes. Also, fasting plasma
C-peptide and insulin showed significant correlations with
NK cell activity. A study by Zhang et al.17 found that type 1
diabetes patients with severely reduced insulin levels also had
decreased NK cells. In addition, expression of NKG2D, an
NK cell receptor, was reduced. NK cell production of IFN-c,
which is essential for immune system function, was also
impaired. A study by Rodacki et al.18 also found that NK
cell activity in patients with long-standing type 1 diabetes
was lower than that of normal controls, in addition to
NKG2D expression. These data, along with the present
results, suggest that insulin deficiency might be associated
with impaired NK cell function. In the prediabetes state,
there is a compensatory increase in insulin secretion to over-
come hyperglycemia, and it might explain why there was no
reduction in NK cell activity in prediabetes patients. How-
ever, when prediabetes patients progress to overt diabetes,
their islet function is reported to be approximately 50% of
individuals with NGT, and consequently might be related to
a reduced NK cell activity.
In addition, previous reports show that low physical inactiv-
ity or unhealthy metabolic status contributes to impaired NK
cell function16. Based on these reports, we investigated correla-
tions between NK cell activity and biochemical parameters
related to diabetes, obesity and metabolic syndrome. However,
other than FPG, 2hPG and HbA1c, no significant correlation
was noted between NK cell activity and body mass index, total
cholesterol, triglyceride, high-density lipoprotein cholesterol,
and low-density lipoprotein cholesterol. Furthermore, although
some studies showed differences in NK cell function at different
levels of hyperglycemia, when we carried out subgroup analysis
on the relationship between NK cell activity and these meta-
bolic parameters, we did not find any significant differences.
The lack of significance might be due to a small number of
study participants in our study.
The present study had several limitations. First, this was a
small cross-sectional study of 49 people at a single center.
Accordingly, there is a risk of bias in this study. Due to the
characteristics of a cross-sectional study, changes in NK cell
activity related to differences in fasting plasma glucose or
HbA1c over time cannot be identified, and it is difficult to
explain the actual relationship between blood glucose
management and NK cell activity in patients with type 2 dia-
betes. A future large-scale study with more participants is
required to investigate the relationship between NK cell activity
and diabetes, blood glucose control, and dyslipidemia. It is also
necessary to determine the relevance of changes in NK cell
activity through classification and analysis of blood glucose or
HbA1c results.
In conclusion, NK cell activity is significantly lower in
patients with type 2 diabetes compared with NGT and predia-
betes patients. NK cell activity significantly decreases linearly
with the increase in blood glucose level. The study supports the
hypothesis that the increasing prevalence of infectious diseases
and malignancy in type 2 diabetes patients is associated with
decreased immune function. Future efforts are required to rede-
fine the relationship between type 2 diabetes mellitus and NK
cell activity, and to provide a way to reduce the incidence of
infectious diseases and cancer by carrying out large-scale studies
of patients with type 2 diabetes.
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